FORT LAUDERDALE, Fla., May 21 /PRNewswire/ -- Newbridge Securities Corporation today announced the quarterly rebalancing and reconstitution of its Newbridge Nanotechnology Index (NYSEArca:...
LONDON, Oct. 4 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) today announces positive results of a Phase III clinical trial for Lodotra(TM), a new, modified-release tablet...
LONDON, Sept. 22 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) announces today that as part of the Company's ongoing initiatives to increase operational efficiency the...
Euro 15 million upfront and Euro 70 million in milestones Double Digit Royalties LONDON, Sept. 6 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) announces today that it has...
LONDON, Sept. 5 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE:Nasdaq:LSE:SKYE) announces today that the Company will issue its interim results for the six months ended 30 June 2006 to the...
LONDON, June 28 /PRNewswire-FirstCall/ -- The Annual General Meeting of SkyePharma plc (LSE:SKPLSE:Nasdaq:LSE:SKYE) was held in London today. All resolutions were passed, with the minimum...
LONDON, May 17 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces the appointment of Dr Ken Cunningham, Chief Operating Officer, as a Director of the Company. It was...
LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) and Kos Pharmaceuticals, Inc. (Nasdaq: KOSP, "Kos") will host a joint teleconference later today to discuss the US...
LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces today that it has entered into an agreement with Kos Pharmaceuticals, Inc. (NASDAQ:KOSP) ("Kos") to...
Innovative Single Epidural Injection 48 Hours of Post-Surgical Pain Relief LONDON, April 28 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE:Nasdaq:LSE:SKYE)) announces today that the UK...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.